EL7.AI
StocksMedium•18 November 2026•
3 min read

Eli Lilly shares close at $1,415.55 after U.S. approval for Mounjaro

Key Facts

1Eli Lilly shares closed at $1,415.55 on November 17, 2026.
2The U.S. Food and Drug Administration approved Mounjaro on August 28, 2026, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk.
3The SURPASS-CVOT trial included 13,299 participants at 640 sites in 30 countries.
4Mounjaro recorded an 8% lower rate of the specified cardiovascular events compared with Trulicity, and the estimated hazard ratio was 0.92.
5The reason for the Canadian notice of compliance issued on April 2, 2026, was an update to the product monograph with new safety information.

Eli Lilly shares closed at $1,415.55 on November 17, 2026, according to available EL7 data. This comes as the company’s Mounjaro faces a significant U.S. regulatory development, after the Food and Drug Administration approved it on August 28, 2026, to reduce the risk of major adverse cardiovascular events. The approved group includes adults with type 2 diabetes who are at high risk. Available Canadian records do not establish that a new approval for this use was issued there. The company had announced that the drug became available in Canada in November 2023 to treat adults with type 2 diabetes, alongside diet and exercise to improve blood sugar control.

Eli Lilly announced the U.S. approval on August 28, 2026, specifying its aim as reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk. The approval is based on the SURPASS-CVOT trial, which included 13,299 participants at 640 sites across 30 countries. The trial compared Mounjaro with Trulicity, a GLP-1 drug with proven cardiovascular benefit, according to the company’s statement. Kenneth Custer of Lilly said heart disease is the “leading cause of death” among people with type 2 diabetes. He added that the company tested Mounjaro against a drug “with proven cardiovascular benefit,” describing this as a higher standard for the test.

The trial results showed that Mounjaro was noninferior to Trulicity, with an 8% lower rate of the composite of cardiovascular death, heart attack or stroke. The estimated hazard ratio for time to first occurrence of one of these events was 0.92, according to the company. This result compares Mounjaro with an active treatment with proven cardiovascular benefit and does not mean the drug proved superior to it. The U.S. approval tied the drug’s use to the group specified in the trial and to reducing the risk of major adverse cardiovascular events. The Canadian records that could be verified did not establish that the authorized use in Canada had been expanded to include this purpose.

In Canada, the available notice of compliance dates to April 2, 2026, and was issued because the product monograph was updated with new safety information, according to Health Canada’s record. The database of products lists Mounjaro’s status as “Approved,” and the displayed monograph is dated June 23, 2026. But these two records do not establish a new cardiovascular approval. Lilly Canada’s announcement on November 2, 2023, said Mounjaro had become available in Canada to treat adults with type 2 diabetes, as an adjunct to diet and exercise to improve blood sugar control. Health Canada’s notice issued in March 2023 also specified the authorized indication as improving blood sugar control in adults with type 2 diabetes.

Open on chart